肺炎链球菌疫苗市场 - 全球产业规模、份额、趋势、机会和预测，按类型、按适应症、按产品、按分布、按地区和竞争进行细分，2020-2030 年预测

2024 年全球肺炎球菌疫苗市场价值为 96.3 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 6.26%。全球肺炎链球菌疫苗市场是製药和医疗保健产业的重要部分，主要用于预防肺炎链球菌细菌引起的感染。肺炎链球菌感染可导致多种疾病，包括肺炎、脑膜炎和败血症，并对公共卫生构成重大威胁，尤其是对幼儿和老年人。例如，根据世界卫生组织2023年的估计，肺炎球菌感染每年在全球造成约160万人死亡，其中近100万人死亡发生在五岁以下的儿童。鑑于肺炎球菌病对儿童死亡率的巨大影响，世卫组织将其列为需要优先接种的疾病。为了对抗这种疾病，该组织强烈建议使用13价肺炎链球菌结合疫苗（PCV）作为有效的预防措施。这些疫苗在减少儿童肺炎、脑膜炎和败血症等严重感染方面发挥着至关重要的作用，特别是在医疗保健有限和疾病盛行率高的地区。

主要市场驱动因素

全球对肺炎球菌疾病的认识不断提高

主要市场挑战

经济差距

主要市场趋势

下一代疫苗

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球肺炎链球菌疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（结合疫苗、多醣体疫苗）
  • 依适应症（支气管炎、脑膜炎、肺炎、败血症）
  • 按产品（Pneumovax23、Prevnar 13、Synflorix）
  • 按分布（政府机关、非政府组织）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 按类型
  • 按适应症
  • 按产品
  • 按分布
  • 按地区

第 6 章：北美肺炎链球菌疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲肺炎链球菌疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太地区肺炎链球菌疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美洲肺炎链球菌疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲肺炎链球菌疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

第 15 章：策略建议

第16章调查会社について・免责事项

Global Pneumococcal Vaccine Market was valued at USD 9.63 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.26% through 2030. The global pneumococcal vaccine market is a crucial segment of the pharmaceutical and healthcare industry, primarily aimed at preventing infections caused by Streptococcus pneumoniae bacteria. Pneumococcal infections can lead to various illnesses, including pneumonia, meningitis, and sepsis, and they pose a significant public health threat, particularly to young children and the elderly. For instance, according to WHO estimates in 2023, pneumococcal infections cause approximately 1.6 million deaths worldwide each year, with nearly one million fatalities occurring in children under the age of five. Given its significant impact on child mortality, WHO classifies pneumococcal disease as a high-priority condition for vaccination. To combat this, the organization strongly recommends the use of 13-valent pneumococcal conjugate vaccines (PCVs) as an effective preventive measure. These vaccines play a crucial role in reducing severe infections such as pneumonia, meningitis, and sepsis in young children, particularly in regions with limited healthcare access and high disease prevalence.

Key Market Drivers

Rising Global Awareness of Pneumococcal Diseases

One of the fundamental reasons behind the growth of the pneumococcal vaccine market is the increasing understanding of the serious health consequences posed by pneumococcal diseases. Medical professionals, policymakers, and the general public are becoming more aware of the debilitating and potentially fatal nature of these infections, leading to a heightened sense of urgency in preventing them. For instance, in June 2023, Sanofi and SK bioscience announced positive results from phase II clinical trials of their 21-valent conjugate vaccine candidate. The findings suggest that GBP410 may provide broader serotype coverage compared to existing vaccines, potentially expanding its market share. Based on these promising results, the companies plan to advance to phase III trials in 2024, with the goal of obtaining final data by 2027.

Public health organizations and advocacy groups have played a pivotal role in disseminating information about pneumococcal diseases. Their efforts include educational campaigns, public service announcements, and initiatives that emphasize the importance of vaccination. As individuals become better informed, they are more likely to seek out and request pneumococcal vaccines.

Key Market Challenges

Economic Disparities

One of the most prominent challenges is the economic disparity among nations. High-income countries often have better access to pneumococcal vaccines due to robust healthcare infrastructures and funding. In contrast, low- and middle-income countries struggle to afford these vaccines, leading to unequal access and health disparities.

Key Market Trends

Next-Generation Vaccines

Advancements in vaccine technology are paving the way for next-generation pneumococcal vaccines. These vaccines are designed to offer broader protection against a wider range of pneumococcal serotypes. By harnessing innovative formulations and targeting evolving bacterial strains, next-gen vaccines are poised to enhance vaccine effectiveness and durability.

Key Market Players

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

Report Scope:

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumococcal Vaccine Market, By Type:

• Conjugate Vaccines
• Polysaccharide Vaccines

Pneumococcal Vaccine Market, By Indication:

• Bronchitis
• Meningitis
• Pneumonia
• Sepsis

Pneumococcal Vaccine Market, By Product:

• Pneumovax23
• Prevnar 13
• Synflorix

Pneumococcal Vaccine Market, By Distribution:

• Government Authorities
• Non-Governmental Organizations

Pneumococcal Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.

Available Customizations:

Global Pneumococcal Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumococcal Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 5.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 5.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 5.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Indication
  • 5.3.3. By Product
  • 5.3.4. By Distribution
  • 5.3.5. By Region

6. North America Pneumococcal Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 6.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 6.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 6.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pneumococcal Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Distribution
  • 6.3.2. Canada Pneumococcal Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Distribution
  • 6.3.3. Mexico Pneumococcal Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Distribution

7. Europe Pneumococcal Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 7.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 7.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 7.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pneumococcal Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Distribution
  • 7.3.2. United Kingdom Pneumococcal Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Distribution
  • 7.3.3. France Pneumococcal Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Distribution
  • 7.3.4. Italy Pneumococcal Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Distribution
  • 7.3.5. Spain Pneumococcal Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Distribution

8. Asia-Pacific Pneumococcal Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 8.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 8.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 8.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pneumococcal Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Distribution
  • 8.3.2. Japan Pneumococcal Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Distribution
  • 8.3.3. India Pneumococcal Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Distribution
  • 8.3.4. Australia Pneumococcal Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Distribution
  • 8.3.5. South Korea Pneumococcal Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Distribution

9. South America Pneumococcal Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 9.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 9.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 9.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pneumococcal Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Distribution
  • 9.3.2. Argentina Pneumococcal Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Distribution
  • 9.3.3. Colombia Pneumococcal Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Distribution

10. Middle East and Africa Pneumococcal Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 10.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 10.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 10.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pneumococcal Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Distribution
  • 10.3.2. Saudi Arabia Pneumococcal Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Distribution
  • 10.3.3. UAE Pneumococcal Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Distribution
  • 10.3.4. Kuwait Pneumococcal Vaccine Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Product
      • 10.3.4.2.4. By Distribution

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. GSK PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc
• 14.3. Merck KGaA
• 14.4. Serum Institute of India Pvt Ltd
• 14.5. CSL Ltd
• 14.6. Sanofi SA
• 14.7. Walvax Biotechnology Co., Ltd
• 14.8. Beijing Minhai Biotechnology Limited Company
• 14.9. AstraZeneca PLC
• 14.10. BioNTech

15. Strategic Recommendations

16. About Us & Disclaimer